Galmed Pharmaceuticals Announces The Filing Of A Provisional Patent Application For The Use Of Aramchol For The Treatment Of Lipodystrophy

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, June 9, 2014 (GLOBE NEWSWIRE) -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it filed a provisional patent application in the United States for the use of its drug, aramchol, for the treatment of lipodystrophy.

Help employers find you! Check out all the jobs and post your resume.

Back to news